These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 1632701)
1. A comprehensive multi-institutional study on postoperative adjuvant immunotherapy with oral streptococcal preparation OK-432 for patients after gastric cancer surgery. Kyoto Research Group for Digestive Organ Surgery. Ann Surg; 1992 Jul; 216(1):44-54. PubMed ID: 1632701 [TBL] [Abstract][Full Text] [Related]
2. [Immunity of gut-associated lymphoid tissue and the role of the oral immunotherapy in multi-disciplinary treatment of the digestive organ cancer]. Nio Y; Tobe T Nihon Geka Gakkai Zasshi; 1989 Sep; 90(9):1436-8. PubMed ID: 2586435 [TBL] [Abstract][Full Text] [Related]
3. Intratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer. A randomized trial. Cooperative Study Group of Preoperative Intratumoral Immunotherapy for Cancer. Tanaka N; Gouchi A; Ohara T; Mannami T; Konaga E; Fuchimoto S; Okamura S; Sato K; Orita K Cancer; 1994 Dec; 74(12):3097-103. PubMed ID: 7982173 [TBL] [Abstract][Full Text] [Related]
4. The efficacy of adjuvant immunochemotherapy with OK-432 after curative resection of gastric cancer: an individual patient data meta-analysis of randomized controlled trials. Oba MS; Teramukai S; Ohashi Y; Ogawa K; Maehara Y; Sakamoto J Gastric Cancer; 2016 Apr; 19(2):616-624. PubMed ID: 25804300 [TBL] [Abstract][Full Text] [Related]
5. Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Maehara Y; Okuyama T; Kakeji Y; Baba H; Furusawa M; Sugimachi K Am J Surg; 1994 Jul; 168(1):36-40. PubMed ID: 8024097 [TBL] [Abstract][Full Text] [Related]
6. The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients. Gochi A; Orita K; Fuchimoto S; Tanaka N; Ogawa N Br J Cancer; 2001 Feb; 84(4):443-51. PubMed ID: 11207036 [TBL] [Abstract][Full Text] [Related]
7. [A double blind study of the evaluation of the optimal dose and its frequency in oral administration of OK-432 (Picibanil) by immunological parameters (the 1st report)]. Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S Nihon Gan Chiryo Gakkai Shi; 1990 Apr; 25(4):799-811. PubMed ID: 2196311 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials. Sakamoto J; Teramukai S; Nakazato H; Sato Y; Uchino J; Taguchi T; Ryoma Y; Ohashi Y J Immunother; 2002; 25(5):405-12. PubMed ID: 12218778 [TBL] [Abstract][Full Text] [Related]
9. Postoperative chemotherapy including intraperitoneal and intradermal administration of the streptococcal preparation OK-432 for patients with gastric cancer and peritoneal dissemination: a prospective randomized study. Sugimachi K; Maehara Y; Akazawa K; Kondo Y; Kunii Y; Kitamura M; Yamaoka H; Takahashi Y; Kito T; Katou M Cancer Chemother Pharmacol; 1994; 33(5):366-70. PubMed ID: 8306409 [TBL] [Abstract][Full Text] [Related]
10. Orally administered streptococcal preparation, OK-432 augments the antitumor immunity of patients with gastric or colorectal cancer. Nio Y; Ohgaki K; Tsuchitani T; Imai S; Shiraishi T; Tobe T Biotherapy; 1990; 2(3):213-22. PubMed ID: 2206774 [TBL] [Abstract][Full Text] [Related]
11. Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Kim JP; Kwon OJ; Oh ST; Yang HK Ann Surg; 1992 Sep; 216(3):269-78; discussion 278-9. PubMed ID: 1417176 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of streptococcal preparation OK-432 for gastric cancer patients--comparison between intradermal and intramuscular injection. Hanaue H; Kurosawa T; Yoshizaki S; Shikata J Jpn J Surg; 1984 May; 14(3):191-7. PubMed ID: 6611437 [TBL] [Abstract][Full Text] [Related]
13. Peri-operative immunotherapy with OK-432. Yokota M; Tagawa Y; Okada D; Yasutake T; Mine Y; Ishikawa H; Miyashita K; Tomita M; Tabuchi S Biotherapy; 1990; 2(3):207-12. PubMed ID: 2206773 [TBL] [Abstract][Full Text] [Related]
14. [A double blind study to evaluate the optimal dose and its frequency for oral administration of OK-432 (picibanil) by immunological parameters (the 2nd report)]. Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):997-1012. PubMed ID: 2202770 [TBL] [Abstract][Full Text] [Related]
15. [A controlled study of surgical adjuvant chemoimmunotherapy with FT-207 and OK-432 for advanced stomach cancer: the fourth study]. Yamamura Y; Yasue M; Nakazato H; Ota K Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):541-8. PubMed ID: 3923941 [TBL] [Abstract][Full Text] [Related]
16. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment. Yamaguchi Y; Ohshita A; Kawabuchi Y; Hihara J; Miyahara E; Noma K; Toge T Int J Oncol; 2004 Apr; 24(4):959-66. PubMed ID: 15010836 [TBL] [Abstract][Full Text] [Related]
17. [Adjuvant immunochemotherapy combined with OK-432 following surgery of stomach cancer]. Yamamura Y; Yasue M; Kito T; Nakazato H; Yamada E Gan To Kagaku Ryoho; 1983 Jul; 10(7):1603-9. PubMed ID: 6409009 [TBL] [Abstract][Full Text] [Related]
18. OK-432-combined adoptive immunotherapy as a prognostic factor in peritoneal metastasis from gastric cancer. Mise K; Kan N; Okino T; Moriguchi Y; Harada T; Ichinose Y; Inoue K Surg Today; 1994; 24(1):54-8. PubMed ID: 8054776 [TBL] [Abstract][Full Text] [Related]
19. [Immunotherapy of gastric cancer]. Kan N; Ohgaki K; Okino T; Nakanishi M; Nio Y; Inoue K; Tobe T Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):755-62. PubMed ID: 3291771 [TBL] [Abstract][Full Text] [Related]
20. [Adjuvant chemotherapy with UFT or UFT with OK-432 to patients with gastric and colorectal cancer. Kanto Adjuvant Study Group]. Konishi T; Idezuki Y; Watanabe H; Haga S; Ushirokouji Y; Shinohara K; Shibusawa M; Bandai Y; Hiraishi M; Murata N; Yabe K; Yamamura T; Yumoto S; Gunji A; Nishigaki M Gan To Kagaku Ryoho; 1998 May; 25(6):887-900. PubMed ID: 9617328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]